Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $28.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
